Patents Examined by M Franco G Salvoza
  • AAV-based conditional expression system
    Patent number: 11155831
    Abstract: The present invention relates to a cell comprising (aa) a nucleic acid comprising in 5? to 3? direction (i) at least one adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; (ii) a promoter which is capable of being activated by (a) helper polypeptide(s) and optionally (a) helper polynucleotide(s); and (iii) a transgenic coding sequence under the control of said promoter of (aa)(ii); and (ab) a nucleic acid comprising in 5? to 3? direction (i) a promoter which is capable of being activated by said helper polypeptide(s) and optionally said helper polynucleotide(s); and (ii) at least one AAV rep gene coding sequence under the control of said promoter of (ab)(i); wherein said cell does not comprise an AAV cap gene and/or is not able to express any AAV cap gene product.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 26, 2021
    Inventors: Ulrich Koszinowski, Simona Langer, Zsolt Ruzsics, Christian Thirion
  • Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
    Patent number: 11149069
    Abstract: The invention provides compositions and methods related to conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: October 19, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Joseph Sodroski, Youdong Mao
  • Adeno-associated virus compositions for targeted gene therapy
    Patent number: 11149256
    Abstract: Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain, and lung. The rAAV compositions described herein also have tropisms showing decreased specificity and decreased efficiency of viral transduction in an off-target cell type, for e.g., the liver. The rAAV compositions described herein encapsidate a transgene, such a therapeutic nucleic acid. Upon systemic delivery to a subject, the rAAV is capable of increased specificity and increased transduction of the transgene in a target cell-type, as compared to a parental or reference AAV.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 19, 2021
    Assignee: California Institute of Technology
    Inventors: Viviana Gradinaru, Nicholas C. Flytzanis, Nicholas Goeden
  • Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
    Patent number: 11135283
    Abstract: The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 5, 2021
    Assignee: Immune Design Corp.
    Inventors: Peter Lars Aksel Berglund, Jacob Freeman Archer, Tsai-Yu Lin
  • Use of vista agonists and antagonists to suppress or enhance humoral immunity
    Patent number: 11123426
    Abstract: Methods for alleviating the suppression of humoral immunity by myeloid-dependent suppressor cells (MDSCs) are provided which include the administration of a VISTA antagonist and an iNOS/NO inhibitor in a subject in need thereof, e.g., subjects with cancer or infectious disease wherein VISTA is aberrantly expressed. This combination has been discovered to elicit a synergistic or additive effect on alleviating suppression of humoral immunity by VISTA which is elicited by MDSCs.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 21, 2021
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Kathy A. Green, Li Wang, Randolph J. Noelle, William R. Green
  • Baculovirus and composition for detection and preventing of porcine epidemic diarrhea virus infection
    Patent number: 11123424
    Abstract: A baculovirus displaying a porcine epidemic diarrhea virus S protein or S1 domain thereof is provided for preventing porcine epidemic diarrhea virus infection.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 21, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Yu-Chan Chao, Wei-Ting Hsu, Hui-Wen Chang, Chia-Yu Chang
  • Modulators of toll-like receptors for the treatment of HIV
    Patent number: 11116774
    Abstract: Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula II: and pharmaceutically acceptable salts thereof, useful in treating HIV infections.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 14, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Romas Geleziunas, Joseph E. Hesselgesser
  • Chimeric norovirus P particle and preparation and use thereof
    Patent number: 11116831
    Abstract: Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A?1-m peptide (m being an integer ranging from 6 to 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also provided are a nucleotide sequence encoding the recombinant P particle, a pharmaceutical composition comprising same and a use thereof for preparing a medicament for treating or preventing Alzheimer's disease. Also provided is a method for preparing the recombinant P particle.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 14, 2021
    Assignees: Changchun BCHT Biotechnology Co., Jilin University
    Inventors: Wei Kong, Hui Wu, Chunlai Jiang, Xianghui Yu, Lu Fu, Yingnan Li
  • Vaccine against infectious bronchitis
    Patent number: 11103573
    Abstract: Poultry vaccines against infectious bronchitis and Turkey Rhinotracheitis are provided. The vaccines are adjuvanted with oil emulsion containing an immunostimulatory oligonucleotide. The methods of using the vaccines are also provided.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 31, 2021
    Assignee: Zoetis Services LLC
    Inventors: Carla Maria Batista de Freitas, Maria Carolina Ferreira dos Santos, Paul Joseph Dominowski, Harmen Jacob Geerligs
  • Methods of predicting ancestral virus sequences and uses thereof
    Patent number: 11104885
    Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: August 31, 2021
    Assignees: The Schepens Eye Research Institute, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Luk H. Vandenberghe, Eric Zinn
  • AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
    Patent number: 11078238
    Abstract: This disclosure relates to variant AAVrh.10 particles engineered to escape host neutralizing antibodies but retain or improve transduction efficiency, and their use as gene delivery vehicles.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 3, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Mavis Agbandje-McKenna, Mario Mietzsch
  • Prefusion PIV F immunogens and their use
    Patent number: 11078239
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 3, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Vaccine composition for naive subjects
    Patent number: 11065325
    Abstract: The invention relates to nasally-administered vaccine compositions effective in naive subjects such as children. Further, the vaccine composition is suitable for vaccinating the general population during a pandemic. One aspect of the invention is directed to the paediatric use of the vaccine of the invention including a vaccine effective in children against seasonal influenza virus strains. A further aspect of the invention is directed to subjects of all age groups when the composition is for pandemic use.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 20, 2021
    Assignee: Eurocine Vaccines AB
    Inventors: Hans Arwidsson, Anna-Karin Maltais
  • Stabilisation method for viruses or bacteria
    Patent number: 11060068
    Abstract: The present invention relates to a method for stabilising viruses or bacteria, the method comprising embedding the viruses or bacteria in an aqueous solution, wherein the solution comprises: (i) at least three different amino acids; or (ii) at least one dipeptide or tripeptide and wherein the solution is free or substantially free of sugar(s), silanes and protein(s).
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 13, 2021
    Assignee: Leukocare AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter
  • Stabilised FMDV capsids
    Patent number: 11053286
    Abstract: The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: July 6, 2021
    Assignee: The Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Human rhinovirus vaccine
    Patent number: 11040095
    Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 22, 2021
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11041171
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 22, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11034977
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
    Patent number: 11034976
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Mutant of adeno-associated virus (AAV) capsid protein
    Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno